These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 25476554)

  • 1. Experience with outcomes research into the real-world effectiveness of novel therapies in Dutch daily practice from the context of conditional reimbursement.
    Gaultney JG; Franken MG; Uyl-de Groot CA; Redekop WK; Huijgens PC; van der Holt B; Lokhorst HM; Sonneveld P
    Health Policy; 2015 Feb; 119(2):186-94. PubMed ID: 25476554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Policymaker, please consider your needs carefully: does outcomes research in relapsed or refractory multiple myeloma reduce policymaker uncertainty regarding value for money of bortezomib?
    Franken MG; Gaultney JG; Blommestein HM; Huijgens PC; Sonneveld P; Redekop WK; Uyl-de Groot CA
    Value Health; 2014 Mar; 17(2):245-53. PubMed ID: 24636383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guideline Adherence Regarding the Use of Expensive Drugs in Daily Practice: The Examples of Trastuzumab in Breast Cancer and Bortezomib in Multiple Myeloma.
    Boons CC; Wagner C; Hugtenburg JG
    Oncol Res Treat; 2016; 39(7-8):417-22. PubMed ID: 27486994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cost-effectiveness analysis of real-world treatment for elderly patients with multiple myeloma using a full disease model.
    Blommestein HM; Verelst SG; de Groot S; Huijgens PC; Sonneveld P; Uyl-de Groot CA
    Eur J Haematol; 2016 Feb; 96(2):198-208. PubMed ID: 25892333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real world experience of bortezomib re-treatment for patients with multiple myeloma at first relapse.
    Reyal Y; Popat R; Cheesman S; Rismani A; D'Sa S; Rabin N; Yong K
    Br J Haematol; 2017 May; 177(3):495-497. PubMed ID: 27062387
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib.
    Möller J; Nicklasson L; Murthy A
    J Med Econ; 2011; 14(6):690-7. PubMed ID: 21892856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report.
    Garrison LP; Neumann PJ; Erickson P; Marshall D; Mullins CD
    Value Health; 2007; 10(5):326-35. PubMed ID: 17888097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bortezomib-containing regimens are effective in multiple myeloma--results of a non-interventional phase IV study.
    Knauf W; Tapprich C; Schlag R; Schütz S; Alkemper B; Gaede B; Reschke D; Schmits R; Schwarzer A
    Oncol Res Treat; 2015; 38(4):167-73. PubMed ID: 25877940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents.
    Gaultney JG; Franken MG; Tan SS; Redekop WK; Huijgens PC; Sonneveld P; Uyl-de Groot CA
    J Clin Pharm Ther; 2013 Feb; 38(1):41-7. PubMed ID: 23126374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects.
    Patrizi A; Venturi M; Dika E; Maibach H; Tacchetti P; Brandi G
    Cutan Ocul Toxicol; 2014 Mar; 33(1):1-6. PubMed ID: 23638756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Governance of conditional reimbursement practices in The Netherlands.
    Boon W; Martins L; Koopmanschap M
    Health Policy; 2015 Feb; 119(2):180-5. PubMed ID: 25467790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expanding role of bortezomib in multiple myeloma: nursing implications.
    Colson K; Doss DS; Swift R; Tariman J
    Cancer Nurs; 2008; 31(3):239-49. PubMed ID: 18453881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma.
    Vogl DT; Stadtmauer EA; Richardson PG; Sonneveld P; Schuster MW; Irwin D; Facon T; Harousseau JL; Boral A; Neuwirth R; Anderson KC
    Br J Haematol; 2009 Nov; 147(4):531-4. PubMed ID: 19725827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma.
    Richardson PG; Sonneveld P; Schuster MW; Irwin D; Stadtmauer EA; Facon T; Harousseau JL; Ben-Yehuda D; Lonial S; San Miguel JF; Cavenagh JD; Anderson KC
    Br J Haematol; 2007 Jun; 137(5):429-35. PubMed ID: 17451408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Observational retrospective study to evaluate the effectiveness and safety of treatment schemes with bortezomib for multiple myeloma in our hospital].
    Titos-Arcos JC; León-Villar J; de Arriba de la Fuente F; Moreno Belmonte MJ; Iranzo Fernández MD
    Farm Hosp; 2012; 36(4):275-81. PubMed ID: 22115856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bortezomib in newly diagnosed patients with multiple myeloma: A retrospective analysis from a tertiary care center in India.
    Pragnya C; Linga VG; Thota NK; Gundeti S; Digumarti R
    Indian J Cancer; 2015; 52(4):537-40. PubMed ID: 26960469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conditional reimbursement within the Dutch drug policy.
    Niezen M; de Bont A; Stolk E; Eyck A; Niessen L; Stoevelaar H
    Health Policy; 2007 Nov; 84(1):39-50. PubMed ID: 17207886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Descriptive and prognostic value of patient-reported outcomes: the bortezomib experience in relapsed and refractory multiple myeloma.
    Dubois D; Dhawan R; van de Velde H; Esseltine D; Gupta S; Viala M; de la Loge C
    J Clin Oncol; 2006 Feb; 24(6):976-82. PubMed ID: 16432077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma.
    Niesvizky R; Richardson PG; Rajkumar SV; Coleman M; Rosiñol L; Sonneveld P; Schuster MW; Irwin D; Stadtmauer EA; Facon T; Harousseau JL; Boral AL; Esseltine DL; Anderson KC; Bladé J
    Br J Haematol; 2008 Oct; 143(1):46-53. PubMed ID: 18673366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. "Real-world" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group.
    Katodritou E; Vadikolia C; Lalagianni C; Kotsopoulou M; Papageorgiou G; Kyrtsonis MC; Matsouka P; Giannakoulas N; Kyriakou D; Karras G; Anagnostopoulos N; Michali E; Briasoulis E; Hatzimichael E; Spanoudakis E; Zikos P; Tsakiridou A; Tsionos K; Anargyrou K; Symeonidis A; Maniatis A; Terpos E
    Ann Hematol; 2014 Jan; 93(1):129-39. PubMed ID: 23892921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.